COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Pfizer Inc.
BNT162 Vaccine program
BNT162 program includes 4 vaccine candidates; BNT162b2 has been advanced into phase global trial.

-- The EMA and Health Canada have already begun rolling review of BNT162b2.

-- On Nov.9, interim results from phase 3 trial reported which showed over 90% efficacy.

-- Announced a vaccine efficacy rate of 95% on Nov.18

-- Filed for Emergency Use Authorization to the FDA on Nov.20
The FDA's Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization (EUA) of BNT162b2 on Dec.10
BioNTech SE
Aridis Pharmaceuticals Inc
Positive efficacy data reported from preclinical trial of AR-711 for non-hospitalized mild-to-moderate COVID-19 patients
Phase 1/2 study of AR-711 is expected to be launched in 1H 2021
RedHill Biopharma Ltd.
FDA has cleared Phase 2/3 study of orally administered RHB-107 in patients with symptomatic COVID-19 who do not require hospitalization
Initiation of phase 2/3 trial
BioLineRx Ltd.
Motixafortide for ARDS secondary to COVID-19
Phase I trial of Motixafortide in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19
Results of preliminary analysis expected in H1 2021
Johnson & Johnson
Ad26.COV2.S Vaccine
Phase 3 trial of a two-dose regimen of Ad26.COV2.S, dubbed ENSEMBLE 2
UK National Institute for Health Research (NIHR)
Moderna, Inc
mRNA-1273 Vaccine
Phase III study, dubbed COVE, completed enrollment on Oct.22.

Interim data reported on Nov.16, revealed 94.5% efficacy
Seek Emergency Use Authorization from the FDA and other regulatory authorities
Biological E. Limited
COVID-19 Vaccine Candidate
Phase I/II trial
The results of phase I/II trial are expected to be available by February 2021
Dynavax Technologies Corporation (DVAX), and Baylor College of Medicine
Q BioMed Inc.
MAN-19 to treat complications caused by COVID-19
Phase 1 trial
Phase 1 trial to begin patient enrollment in February 2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
JPMorgan Chase Bank, N.A., a unit of JPMorgan Chase & Co., has agreed to pay $250 million penalty over the bank's failure to maintain adequate internal controls and internal audit over its fiduciary business. In a filing with the U.S. Securities and Exchange Commission, the company said JPMorgan Chase Bank has entered into a resolution with the Office of the Comptroller of the Currency or OCC. Sunbeam Products, Inc. recalled about 942,760 units of Crock-Pot 6-Quart Express Crock Multi-Cookers for potential burn hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include about 28,330 units sold in Canada. Trying to find the perfect gifts for our loved ones has always been a matter of concern. Walmart.com is set to take the pain out of customers this holiday season by adding new features and categories to the Gift Finder tool, which was introduced last year. This, the retail giant believes, will make online shopping easier for gift givers.